HOUSTON INNOVATORS PODCAST EPISODE 46

Houstonian fosters collaboration and mentorship for women in venture capital

Sandy Guitar — along with other Houston female venture capitalists — are gathering virtually to promote networking and friendship amid the pandemic. Photo courtesy of Sandy Guitar

When Sandy Guitar saw that Austin had a group of women in venture capital group that promoted collaboration and networking, she knew Houston had to have one too.

Guitar, who is the managing director of the HX Venture Fund, connected with the Austin group, picked their brains and asked for advice on starting a local iteration, and recruited a few fellow female VC experts in town — and the rest is history.

"There's a part of us as women that understands necessarily that work and life combine," Guitar says on this week's episode of the Houston Innovators Podcast. "Our lives as women don't allow us to segment our lives. The truth is those parts of our lives come together. The more we can do that, the more we can build networks that help us achieve everything we want both professionally and personally."

Now, over a year later, the Women Investing in VC in Houston group has grown to over 30 members — so much that their virtual visits are broken into smaller groups. The group boasts diversity and has representatives across types of funds. To join, women must simply live in Houston and be a venture capital investor. Other than that, the group is unstructured and casual, which fosters an environment where members are allowed to ask a stupid question or speak up on something personal, as Guitar says.

"When you have no dues and very little formality, no structure, no pressure to attend — it's in that setting that you actually build trust. Organically, the friendships come together," she says. "That's what it's really about."

While the group had pre-pandemic beginnings, the model of mentorship and networking is more relevant now than ever. Men and women alike, Guitar says, are not able to silo work and life as we work from home and practice social distancing.

"COVID has made us vulnerable in an entirely new set of ways," she says. "We use our support groups — whatever they are — to help us."

Guitar discusses the group and how what the venture capital industry needs to do to evolve into a more welcoming space for women in the episode of the podcast. You can listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


The Women Investing in VC in Houston group has pivoted to virtual events since the start of COVID-19. Photo courtesy of Sandy Guitar

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted